Cantor Fitzgerald Investment Advisors L.P. Sells 24,820 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Cantor Fitzgerald Investment Advisors L.P. lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 8.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 270,900 shares of the biopharmaceutical company's stock after selling 24,820 shares during the quarter. Bristol Myers Squibb comprises approximately 1.2% of Cantor Fitzgerald Investment Advisors L.P.'s portfolio, making the stock its 25th largest position. Cantor Fitzgerald Investment Advisors L.P.'s holdings in Bristol Myers Squibb were worth $16,522,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Bristol Myers Squibb by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock worth $10,743,262,000 after acquiring an additional 1,373,209 shares in the last quarter. Capital International Investors increased its holdings in shares of Bristol Myers Squibb by 7.5% in the 4th quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after acquiring an additional 3,218,865 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Bristol Myers Squibb by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock valued at $2,505,967,000 after acquiring an additional 1,187,231 shares during the last quarter. Norges Bank purchased a new position in shares of Bristol Myers Squibb in the 4th quarter valued at about $1,989,525,000. Finally, Ameriprise Financial Inc. increased its holdings in shares of Bristol Myers Squibb by 59.9% in the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after acquiring an additional 12,011,983 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Buying and Selling

In related news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on BMY. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. UBS Group decreased their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Finally, Argus raised Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $58.00.

Bristol Myers Squibb Stock Up 0.1%

NYSE:BMY traded up $0.03 during trading hours on Friday, reaching $46.87. The company's stock had a trading volume of 47,283,703 shares, compared to its average volume of 13,081,197. The company has a market cap of $95.38 billion, a price-to-earnings ratio of 17.55, a price-to-earnings-growth ratio of 1.39 and a beta of 0.38. Bristol Myers Squibb Company has a one year low of $39.35 and a one year high of $63.33. The business's 50-day moving average is $48.20 and its 200-day moving average is $54.35. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the prior year, the company earned ($4.40) earnings per share. The business's quarterly revenue was down 5.6% compared to the same quarter last year. Equities research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.29%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.